Vaccine R&D , Orth/Donau.
Global Quality.
Open Forum Infect Dis. 2014 Aug 25;1(2):ofu072. doi: 10.1093/ofid/ofu072. eCollection 2014 Sep.
Neuraminidase-inhibiting (NAi) antibodies have been reported to be an independent correlate of protection from influenza disease, but the NAi antibody response to influenza vaccination has never been assessed in chronically ill or immunocompromised participants. Using an enzyme-linked lectin assay, we demonstrated that 2 immunizations with a Vero cell culture-derived, whole-virus H5N1 A/Vietnam vaccine induces NAi antibodies in 94.3% of chronically ill and 83.8% of immunocompromised participants. A booster with a heterologous A/Indonesia H5N1 vaccine induced comparable NAi antibody titers in both groups and resulted in 100% seropositivity. These data support prepandemic H5N1 vaccination strategies for these highly vulnerable risk groups.
神经氨酸酶抑制（NAi）抗体已被报道为预防流感疾病的独立相关因素，但流感疫苗接种引起的 NAi 抗体反应在慢性疾病患者或免疫功能低下者中从未被评估过。我们使用酶联凝集素检测法证实，用 Vero 细胞培养的全病毒 H5N1 A/越南疫苗进行 2 次免疫接种，可诱导 94.3%的慢性疾病患者和 83.8%的免疫功能低下者产生 NAi 抗体。用异源 A/印度尼西亚 H5N1 疫苗进行加强免疫可在两组中诱导相当的 NAi 抗体滴度，并导致 100%的血清阳性率。这些数据支持对这些高度脆弱的高危人群进行大流行前 H5N1 疫苗接种策略。
